



HAL
open science

Meta-analysis: Factors Affecting Placebo Response Rate in Irritable Bowel Syndrome.

Alexander Ford, Paul Moayyedi

► **To cite this version:**

Alexander Ford, Paul Moayyedi. Meta-analysis: Factors Affecting Placebo Response Rate in Irritable Bowel Syndrome.. *Alimentary Pharmacology and Therapeutics*, 2010, 32 (2), pp.144. 10.1111/j.1365-2036.2010.04328.x . hal-00552561

HAL Id: hal-00552561

<https://hal.science/hal-00552561>

Submitted on 6 Jan 2011

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Meta-analysis: Factors Affecting Placebo Response Rate in Irritable Bowel Syndrome.

Journal:	<i>Alimentary Pharmacology & Therapeutics</i>
Manuscript ID:	APT-0225-2010.R1
Manuscript Type:	Meta-analysis
Date Submitted by the Author:	09-Apr-2010
Complete List of Authors:	Ford, Alexander; St James's University Hospital, Department of Academic Medicine Moayyedi, Paul; McMaster University, Gastroenterology Division
Keywords:	Functional GI diseases < Disease-based, Irritable bowel syndrome < Disease-based, Large intestine < Organ-based, Clinical pharmacology < Topics, Meta-analyses < Topics

Ford *et al.*

1 of 51

TITLE PAGE

Title: Meta-analysis: Factors Affecting Placebo Response Rate in Irritable Bowel Syndrome.

Short running head: Placebo Response Rate in IBS.

Authors: Alexander C Ford¹, Paul Moayyedi².

¹Department of Academic Medicine, St. James's University Hospital, Leeds, UK.

²Gastroenterology Division, McMaster University, Health Sciences Center, Hamilton, Ontario, Canada.

Abbreviations:	5-HT	5-hydroxytryptamine
	b.i.d.	twice daily
	CI	confidence interval
	GI	gastrointestinal
	IBS	irritable bowel syndrome
	MeSH	medical subject headings
	o.d.	once daily
	q.i.d.	four times daily
	RCT	randomised controlled trial
	t.i.d.	three times daily

Ford *et al.*

2 of 51

1
2
3
4 **Correspondence:** Dr. Alex Ford
5
6 Department of Academic Medicine
7
8 Room 7.22
9
10 Clinical Sciences Building
11
12 St. James's University Hospital
13
14 Beckett Street
15
16
17 Leeds
18
19 LS9 7TF
20
21 United Kingdom
22
23 Email: alexfl2399@yahoo.com
24
25 Telephone: +44
26
27 Facsimile: +44
28
29
30
31
32
33

34 **Keywords:** Irritable bowel syndrome
35
36 Meta-analysis
37
38 Randomised controlled trials
39
40
41 Placebo
42
43
44
45
46
47

48 **Word count:** 3936
49
50
51
52
53
54
55
56
57
58
59
60

Ford *et al.*

3 of 51

SUMMARY

Background: Irritable bowel syndrome (IBS) is a functional disorder of the gastrointestinal tract. Magnitude of placebo response rate in treatment trials for IBS, and what factors may influence this, is important.

Aims: To conduct a systematic review and meta-analysis examining this.

Methods: MEDLINE, EMBASE, and the Cochrane central register of controlled trials were searched to identify randomised controlled trials (RCTs) comparing pharmacological therapies with placebo in adult IBS patients. Studies reported either global assessment of IBS symptom cure or improvement, or abdominal pain cure or improvement. Data were extracted as intention-to-treat analyses with drop-outs assumed to be treatment failures, and pooled using a random effects model. Proportion of placebo patients experiencing symptom improvement or resolution was reported, with a 95% confidence interval (CI). Effect of trial characteristics on magnitude of placebo response was examined.

Results: 73 RCTs were eligible, including 8364 patients with IBS allocated to placebo. Pooled placebo response rate across all RCTs was 37.5% (95% CI 34.4%-40.6%). Rates were higher in European RCTs, RCTs that used physician-reported outcomes, and RCTs using shorter duration of therapy.

Conclusions: Placebo response rates across RCTs of pharmacological therapies in IBS were high. Future research should identify patient characteristics predicting placebo response.

Ford *et al.*

4 of 51

INTRODUCTION

Irritable bowel syndrome (IBS) is a common functional gastrointestinal (GI) disorder consisting of abdominal pain in association with a disturbance in bowel habit.

¹ The condition follows a chronic relapsing and remitting course. ^{2,3} Sufferers represent a significant burden to the health service due to the consumption of medical resources, such as consultations in primary and secondary care, ³⁻⁶ investigations, ⁷ drugs, ⁸ and unnecessary surgical procedures. ⁹

Despite evidence from recent meta-analyses demonstrating that some pharmaceutical agents, including antispasmodic drugs, peppermint oil, antidepressants, and drugs acting on the 5-hydroxytryptamine (5-HT) receptor are of benefit for the treatment of IBS in the short-term, ¹⁰⁻¹² there is no medical intervention proven to alter the long-term natural history of the condition, and there is no agreement on a gold-standard for the treatment of IBS.

As a result, whenever a new pharmaceutical agent is developed for IBS it is compared with placebo in a randomised controlled trial (RCT). There is no structural abnormality that can be corrected by successful therapy and response to treatment is therefore assessed by improvement in symptoms. This is a subjective outcome and, in an effort to standardise research, the Rome foundation has made recommendations as to how best to assess response to therapy in treatment trials conducted in IBS and the other functional GI disorders. ¹³

Evidence from the systematic review literature suggests that a significant proportion of patients assigned to placebo will respond to therapy, even in RCTs of therapies for organic GI conditions such as inflammatory bowel disease or peptic ulcer, where mucosal or ulcer healing are the outcomes of interest. ^{14,15} In functional

Ford *et al.*

5 of 51

1
2
3 GI disorders, where trial endpoints are likely to be less tangible than this, the placebo
4 response rate may be even higher. However, despite the fact that there have been
5 numerous published RCTs of pharmacological therapies in IBS this issue has not been
6 well studied. This is important, as high placebo response rates will statistically reduce
7 the possibility of seeing a positive impact of active therapy, and RCTs should be
8 designed to minimise placebo response. We have therefore conducted a systematic
9 review and meta-analysis in order to assess the magnitude of the placebo response rate
10 in treatment trials of IBS, and have examined trial characteristics and features of
11 design that may influence this.
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Ford *et al.*

6 of 51

MATERIALS AND METHODS

Search Strategy and Trial Selection

Studies were identified through a search developed to inform an updated monograph on the management of IBS for the American College of Gastroenterology.

¹⁶ A search of the medical literature was conducted using MEDLINE (1950 to January 2010), EMBASE (1980 to January 2010), and the Cochrane central register of controlled trials (2009). Randomised controlled trials examining the effect of pharmacological therapies in adult patients (over the age of 16 years) with IBS were eligible for inclusion (Box 1). The first period of cross-over RCTs were also eligible for inclusion. In the case of all RCTs the control arm were required to receive placebo. Duration of therapy had to be at least 7 days. The diagnosis of IBS could be based on either a physician's opinion or symptom-based diagnostic criteria, supplemented by the results of investigations to exclude organic disease, where trials deemed this necessary. Trials had to report either a global assessment of IBS symptom cure or improvement, or abdominal pain cure or improvement, after completion of therapy, preferably as reported by the patient, but if this was not recorded then as documented by the investigator or via questionnaire data. Where RCTs included patients with other functional GI disorders, or did not report these types of dichotomous data, but were otherwise eligible for inclusion in the systematic review, we attempted to contact the original investigators in order to obtain further information.

Placebo-controlled trials in irritable bowel syndrome were identified with the terms *irritable bowel syndrome* and *functional diseases, colon* (both as medical subject heading (MeSH) and free text terms), and *IBS, spastic colon, irritable colon,* and *functional adj5 bowel* (as free text terms). These were combined using the set

Ford *et al.*

7 of 51

operator AND with studies identified with the terms: *parasympatholytics*,
scopolamine, *trimebutine*, *muscarinic antagonists*, *butylscopolammonium bromide*,
psychotropic drugs, *antidepressive agents*, *antidepressive agents (tricyclic)*,
desipramine, *imipramine*, *trimipramine*, *doxepin*, *dothiepin*, *nortriptyline*,
amitriptyline, *selective serotonin re-uptake inhibitors*, *paroxetine*, *sertraline*,
fluoxetine, *citalopram*, *venlafaxine*, *serotonin antagonists*, *serotonin agonists*,
cisapride, *receptors (serotonin, 5-HT₃)*, and *receptors (serotonin, 5-HT₄)* (both as
MeSH terms and free text terms), and the following free text terms: *spasmolytics*,
spasmolytic agents, *antispasmodics*, *mebeverine*, *alverine*, *pinaverium bromide*,
otilonium bromide, *cimetropium bromide*, *hyoscine butyl bromide*, *butylscopolamine*,
peppermint oil, *colpermin*, *5-HT₃*, *5-HT₄*, *alosetron*, *cilansetron*, *ramosetron*,
tegaserod, and *renzapride*.

There were no language restrictions and abstracts of the papers identified by the initial search were evaluated by the lead reviewer for appropriateness to the study question, and all potentially relevant papers were obtained and evaluated in detail. Foreign language papers were translated where necessary. Abstract books of conference proceedings between 2001 and 2009 were hand-searched to identify potentially eligible RCTs published only in abstract form. We also contacted pharmaceutical companies and searched the Food and Drug Administration Agency (FDA) website to obtain data from unpublished RCTs. The bibliographies of all identified relevant trials were used to perform a recursive search of the literature. Articles were independently assessed by two reviewers using pre-designed eligibility forms, according to the prospectively defined eligibility criteria. Any disagreement between investigators was resolved by consensus.

Ford *et al.*

8 of 51

Outcome Assessment

The primary outcome assessed was the magnitude of the placebo response rate, in terms of improvement in, or resolution of, global IBS symptoms or abdominal pain, in all RCTs of pharmacological therapies conducted in IBS after cessation of therapy. Secondary outcomes included assessing placebo response rate according to various trial characteristics (see below).

Data Extraction

All data were extracted independently by two reviewers on to a Microsoft Excel spreadsheet (XP professional edition; Microsoft Corp, Redmond, WA, USA) as dichotomous outcomes (global IBS symptoms absent or improved, or abdominal pain absent or improved in the placebo arms of the included RCTs) (Box 2). In addition, the following clinical data were extracted for each trial: year of publication, geographical location, setting (primary, secondary, or tertiary care), number of centres, criteria used to define IBS, IBS subtype according to predominant stool pattern reported by the patient (diarrhoea-predominant, constipation-predominant, or alternating bowel habit), dosing schedule of the placebo, duration of therapy, proportion of trial patients receiving placebo, active pharmacological therapy used, primary outcome measure used to define symptom improvement or cure following therapy (patient versus physician-reported and global IBS symptoms versus abdominal pain or discomfort), whether the method used to generate the randomisation schedule was stated, whether the method of concealment of allocation was stated, and overall trial quality (assessed using the Jadad scale, Box 3).¹⁷ Data were extracted as intention-to-treat analyses, with all drop-outs assumed to be

Ford *et al.*

9 of 51

treatment failures, wherever trial reporting allowed this.

Data Synthesis and Statistical Analysis

Data were pooled using a random effects model, to give a more conservative estimate of the magnitude of the placebo response rate, allowing for any heterogeneity between trials.¹⁸ Outcomes were expressed as the pooled proportion of patients assigned to placebo with global IBS symptoms or abdominal pain absent or improved after completion of therapy, with a 95% confidence interval (CI).

The results of individual RCTs can be diverse, and this inconsistency within a single meta-analysis can be quantified with a statistical test of heterogeneity, to assess whether the variation across trials is due to true heterogeneity, or chance. This quantity is termed I^2 , and its value ranges from 0% to 100%, with 0% representing no observed heterogeneity, and larger values indicating increasing heterogeneity. A value below 50% was chosen to represent low levels of heterogeneity.¹⁹

Subgroup analyses were conducted according to year of publication geographical location, trial setting, single versus multi-centre trials, criteria used to define IBS, predominant stool pattern reported by the patient, dosing schedule of the placebo, duration of therapy, proportion of trial patients receiving placebo, active pharmacological therapy used, primary outcome measure used to define symptom improvement or cure following therapy (patient versus physician-reported and global IBS symptoms versus abdominal pain or discomfort), whether method of randomisation or concealment of allocation were reported, and trial quality according to the Jadad scale. We did not performed meta-regression in this systematic review and meta-analysis, but rather subgroup analyses according to individual trial characteristics, because the former technique evaluates the average of patient

Ford *et al.*

10 of 51

1
2
3 characteristics within each trial, and this summary data may misrepresent individual
4
5 patients within each treatment arm. The technique is therefore vulnerable to giving
6
7 spurious results due to the ecological fallacy.²⁰
8
9

10
11 StatsDirect version 2.4.4 (StatsDirect Ltd, Sale, Cheshire, England) was used
12
13 to generate Forest plots of the pooled proportions of patients assigned to placebo with
14
15 global IBS symptoms or abdominal pain absent or improved after completion of
16
17 therapy, with 95% confidence intervals. Pooled placebo response rates were compared
18
19 between the pre-defined subgroups using the Cochran Q statistic in order to assess for
20
21 any heterogeneity between placebo response rates for the different subgroup analyses
22
23 we conducted and, due to multiple analyses, a P value of < 0.01 was considered
24
25 statistically significant.
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

RESULTS

The search strategy generated 3383 citations of which 177 appeared to be relevant to the systematic review and were retrieved for further assessment (Figure 1). Of these 177 RCTs, 104 were excluded for various reasons leaving 73 eligible trials, ²¹⁻⁹² containing 8364 individuals with IBS who were randomised to receive placebo. Five of these RCTs were published in abstract form only, ^{73-75, 82, 83} and data from two placebo-controlled trials of tegaserod in IBS (B307 and B351) were published in a single document on the FDA website. ⁸⁴ We contacted original investigators in seven of the studies to clarify data or obtain supplementary information. ^{42, 49, 72, 82, 83, 85, 87} Agreement between reviewers for assessment of trial eligibility was good (kappa statistic = 0.90). Characteristics of individual RCTs, including the magnitude of the placebo response in each trial, are provided in Table 1.

Placebo Response Rate in All Trials

The pooled placebo response rate in the 73 RCTs we identified was 37.5% (95% CI 34.4% to 40.6%), with considerable heterogeneity between trials ($I^2 = 86.2\%$, $P < 0.001$). The placebo response rate in individual RCTs varied from 0% in two trials, ^{21, 23} to 91.7%. ⁵⁷ (Figure 2)

Placebo Response Rate According to Year of Publication, Trial Location, Setting, and Number of Centres

Trials were divided into those published before 1999, and those published in 1999 or later, as accepted endpoints for evaluating the success of therapy in IBS treatment trials changed around this point in time. There was, however, no significant

Ford *et al.*

12 of 51

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

difference in placebo response rates between these two time periods (Cochran Q = 0.60, P = 0.44) (Table 2). The majority of RCTs were conducted in Europe,^{21, 22, 24, 26-31, 34-37, 39-41, 46, 48, 49, 51, 53-56, 58, 61, 81, 85, 87-91} and the pooled placebo response rate was highest in these trials at 42.7% (Table 2). This rate was significantly higher than that in RCTs conducted in Asia (25.0%, Cochran Q = 8.8, P = 0.003),^{23, 25, 50, 67, 70, 80} the Middle-East (23.0%, Cochran Q = 9.4, P = 0.002),^{44, 52, 66, 69} and North America (33.0%, Cochran Q = 7.3, P = 0.007).^{38, 42, 45, 47, 59, 60, 62-65, 68, 71, 75, 78, 86, 92} However, the number of Asian and Middle Eastern studies was low (n = 6 and n = 4 respectively) and the differences observed between Asian, Middle-Eastern, and North American RCTs were not statistically significant (Table 2). When the effect of trial setting and number of centres was examined, pooled placebo response rate was very similar in RCTs based in secondary and tertiary care, and in single and multi-centre trials, with no statistically significant difference detected (Cochran Q = 0.08, P = 0.78 for both analyses) (Table 2).

Placebo Response Rate According to Diagnostic Criteria Used to Define IBS and Predominant Stool Pattern Reported by the Patient

A clinical diagnosis (usually according to a physician's assessment) of IBS was the most frequent criteria used to define the presence of the condition,^{21-25, 27-32, 34, 36-41, 45, 48, 50, 51, 53-57, 89} and pooled placebo response rate was highest in trials that used this definition at 42.0% (Table 2), compared with the Rome I or II criteria (36.0% and 34.4% respectively). However, the difference between these rates was not statistically significant (Cochran Q = 1.3, P = 0.25 and Cochran Q = 2.15, P = 0.14 respectively). There were few trials that reported the predominant stool pattern reported by the patient, but some trials recruited diarrhoea or constipation-predominant patients

Ford *et al.*

13 of 51

1
2
3 exclusively,^{32, 44, 52, 64, 67, 70, 71, 73-78, 80, 82-84, 86-91} allowing us to examine the effect of
4
5 this patient characteristic on pooled placebo response rates. No statistically significant
6
7 difference, in terms of pooled placebo response rate, between RCTs recruiting
8
9 constipation-predominant or diarrhoea-predominant IBS patients was detected
10
11 (Cochran Q = 0.6, P = 0.45) (Table 2).
12
13
14
15
16

17 **Placebo Response Rate According to Criteria and Symptom Data Used to Define** 18 19 **Response** 20 21

22 There were only four RCTs that used a physician-reported outcome to define
23 response to therapy,^{34, 36, 37, 56} and the pooled placebo response rate was significantly
24
25 higher in these trials compared to those that used a patient-reported outcome (53.0%
26
27 versus 37.4%, Cochran Q = 7.8, P = 0.005) (Table 2). In terms of symptom data used
28
29 to define response, the majority of studies used improvement or relief of global IBS
30
31 symptoms, though 13 used improvement or relief of abdominal pain or discomfort.^{25,}
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

32, 44, 45, 54, 59, 61-63, 69, 71, 72, 87 There was no significant difference in pooled placebo
response rate according to the symptom data used to define response (Cochran Q =
0.6, P = 0.43) (Table 2).

46 **Placebo Response Rate According to Dosing Schedule, Duration of Therapy, and** 47 48 **Proportion of Trial Patients Assigned to Placebo** 49

50 The commonest dosing schedule used in eligible RCTs was three times daily,
51
52
53
54
55
56
57
58
59
60
24, 27-33, 35-37, 39-41, 54, 56, 58, 69, 73-75, 87-90 and pooled placebo response rate was highest in
these trials at 43.0%, compared with RCTs that used a once or twice daily schedule
(32.2% and 36.0% respectively) (Table 2), but again these differences did not reach
formal statistical significance (Cochran Q = 4.7, P = 0.03 and Cochran Q = 3.2, P =

Ford *et al.*

14 of 51

0.07 respectively). Duration of therapy varied from 1 week to 48 weeks. Pooled placebo response rate was highest in trials using 1 to 4 weeks of therapy at 46.0%,^{24, 25, 27, 30, 32, 34, 36, 38-41, 51, 54-57, 77, 86, 92} which was significantly higher than in RCTs that used more than 8 weeks of therapy (34.0%, Cochran Q = 8.5, P = 0.004),^{21-23, 28, 29, 33, 35, 37, 42-44, 47, 53, 58-67, 70-76, 78-84, 87-91} but not trials using 5 to 8 weeks of therapy (39.8%, Cochran Q = 0.8, P = 0.37) (Table 2).^{26, 31, 45, 46, 48-50, 52, 68, 69, 85} The majority of trials assigned patients to active therapy or placebo in a 1:1 ratio, and pooled placebo response rate was higher in these RCTs compared with trials where fewer patients received placebo than received active therapy,^{42, 59-61, 64, 70, 71, 76, 77, 82-87} although this difference was not statistically significant (Cochran Q = 2.3, P = 0.13) (Table 2).

Placebo Response Rate According to Active Pharmacological Therapy Used

Antispasmodic drugs were the active pharmacological agent used in the greatest number of trials.^{21, 22, 27-41, 54-57} Pooled placebo response rates were highest in RCTs that used antispasmodics or mixed 5-HT₃ antagonists / 5-HT₄ agonists (45.0% for both). Whilst there was a trend for the observed response rate to be higher in RCTs that used antispasmodics compared with those using peppermint oil, 5-HT₃ antagonists, or 5-HT₄ agonists these differences were not statistically significant (Cochran Q = 4.5, P = 0.03 for peppermint oil and Cochran Q = 3.1, P = 0.08 for both 5-HT₃ antagonists and 5-HT₄ agonists) (Table 2). There was also a trend for the response rate to be higher in RCTs that used mixed 5-HT₃ antagonists / 5-HT₄ agonists compared with those that used peppermint oil, but again this difference did not reach statistical significance (Cochran Q = 3.2, P = 0.07) (Table 2).

Placebo Response Rate According to Reporting of Method Used to Generate the Randomisation Schedule or to Conceal Allocation

The majority of RCTs did not report either of these features of their design. Pooled placebo response rate was slightly lower in trials that stated the method used to generate the randomisation schedule, but this difference was not statistically significant (Cochran Q = 1.4, P = 0.24) (Table 2). The pooled placebo response rate was almost identical when RCTs were subgrouped according to whether or not the method used to conceal treatment allocation was reported.

Placebo Response Rate According to Trial Quality

Most RCTs scored 4 or more on the Jadad scale. When pooled placebo response rates according to trial quality were assessed, these were highest in those with a score of 3 (40.0%), but the response rate was not significantly lower in studies with a score of 4 (37.8%, Cochran Q = 0.15, P = 0.70) or 5 (36.0%, Cochran Q = 0.51, P = 0.47).

Ford *et al.*

16 of 51

DISCUSSION

This systematic review and meta-analysis of placebo-controlled randomised trials conducted in IBS patients has demonstrated a pooled placebo response rate of 37.5%. The rate was significantly higher in European RCTs compared with those conducted in Asia, the Middle-East, or North America, in trials with a treatment duration from 1 to 4 weeks compared with those that used 8 weeks or more of therapy, and in RCTs that used a physician-reported outcome to define response to therapy compared with those that used a patient-reported endpoint, though in the latter case there were only four studies that used a physician-reported outcome that provided data for the analysis.

Pooled placebo response rates were generally higher in RCTs using clinical criteria to define the presence of IBS, compared with those that used the Rome I or II criteria, trials that used a three times daily dosing schedule, trials that assigned patients to placebo or active therapy in a 1:1 ratio, trials of antispasmodics and mixed 5-HT₃ antagonists / 5-HT₄ agonists, and trials of lower quality according to the Jadad scale, but none of these differences reached formal statistical significance. Specific features of RCT design such as trial setting, number of involved centres, predominant stool pattern of recruited patients, as well as whether or not investigators reported the method used to generate the randomisation schedule and to conceal treatment allocation appeared to have little effect on pooled placebo response rates in our analyses, nor did the year of publication of the trial.

Strengths of the present study include the search strategy, which was exhaustive, and the fact that we contacted original investigators in order to obtain supplementary data in some cases, in order to maximise the number of identified

Ford *et al.*

17 of 51

1
2
3 RCTs providing data for these analyses. We assessed the impact of individual trial
4
5 characteristics on pooled placebo response rates in subgroup analyses. We also
6
7 performed an intention-to-treat analysis, where all drop-outs were assumed to be
8
9 treatment failures, and used a random effects model to provide a more conservative
10
11 estimate of the pooled placebo response rate, meaning that the magnitude of this
12
13 effect is unlikely to have been overestimated. Weaknesses of the study include the
14
15 fact that there was statistically significant heterogeneity when trial data were pooled,
16
17 which was not explained by any of our subgroup analyses, and the fact that, without
18
19 access to individual patient data it is difficult to draw any conclusions about specific
20
21 patient characteristics that may have contributed to the findings of our study.
22
23
24
25
26

27 There has been a previously published systematic review and meta-analysis
28
29 that has examined this issue.⁹³ The authors identified 45 placebo-controlled trials,
30
31 containing 3352 individuals with IBS who were randomised to receive placebo. They
32
33 reported a placebo response rate of 40% when data for all eligible trials were pooled.
34
35 The response rate was significantly lower in studies that used the Rome criteria to
36
37 define the presence of IBS, but there were no other features of the studies identified
38
39 that they examined, including trial duration, score on the Jadad scale, and type of
40
41 active pharmacological therapy, which predicted placebo response rate. There are
42
43 several limitations of this study. Firstly, there has been a considerable amount of data
44
45 published in the 5 years since this meta-analysis was conducted. Secondly, the authors
46
47 included RCTs of therapies for IBS that are not accepted as conventional treatments
48
49 for the condition, such as activated charcoal, loxiglumide, and naloxene. Thirdly, they
50
51 included cross-over studies in which data extraction according to initial treatment
52
53 allocation was not possible. Finally, they missed eligible studies that were published
54
55 and available at the time their meta-analysis was conducted. The present study
56
57
58
59
60

Ford *et al.*

18 of 51

1
2
3 therefore provides new and important information about the magnitude of the placebo
4
5 response rate in IBS, as well as examining a larger number of trial characteristics and
6
7 features of design that may influence this.
8
9

10 The finding that placebo response rates were significantly higher in RCTs
11
12 conducted in European populations is novel. Possible explanations for this are
13
14 speculative, but it may be that there are cultural differences that influence the
15
16 magnitude of the placebo effect. The fact that trials with a duration of therapy of
17
18 between 1 and 4 weeks reported a significantly larger placebo effect than trials using
19
20 more than 8 weeks is interesting, and suggests that any observed benefit of placebo in
21
22 the treatment of IBS may ameliorate over time. The trend towards a higher placebo
23
24 response rate seen with an increase in dosing schedule is a phenomenon that has also
25
26 been described when data from healing rates in duodenal ulcer trials were examined.
27
28

29
30
31 ¹⁴ There is evidence from the systematic review literature that RCTs that do not report
32
33 the method used to generate the randomisation schedule and to conceal allocation tend
34
35 to overestimate the efficacy of the active therapy. ⁹⁴ It could therefore be expected that
36
37 placebo response rates would be lower in trials that did not report these features of
38
39 their design, and it is therefore interesting to note that in our analyses these had no
40
41 statistically significant effect on the magnitude of the placebo response.
42
43
44

45 The number of IBS patients achieving response or remission of their
46
47 symptoms with placebo in this study appears to be somewhere between one in two
48
49 and one in three. This information is important for the conduct of future RCTs in the
50
51 condition, as it may be helpful in informing power calculations on which to base trial
52
53 recruitment. Recent trials of renzapride and citalopram in IBS both failed to
54
55 demonstrate any significant benefit of these drugs, ^{68,95} partly due to the high
56
57 response rates observed in the placebo arms of the trials, which meant that the studies
58
59
60

Ford *et al.*

19 of 51

1
2
3 were underpowered to detect a statistically significant difference, and in the case of
4
5 renzapride led the pharmaceutical company that had developed the drug to abandon
6
7 further investment in its clinical development.⁹⁶ Trials that use a longer duration of
8
9 treatment, and use medication given once or twice daily, might be expected to reduce
10
11 the placebo response rate, and may have a better ability to demonstrate the benefit of
12
13 active therapy.
14
15

16
17 In conclusion, this systematic review and meta-analysis has demonstrated a
18
19 pooled placebo response rate in all available RCTs of pharmacological therapies in
20
21 IBS of 37.5%. Future research should concentrate on identifying patient
22
23 characteristics that predict such a response to treatment, perhaps using trial data at the
24
25 individual patient level.
26
27
28
29
30

31 **ACKNOWLEDGEMENTS**

32 **Authors' Declaration of Personal Interests:**

33
34
35
36 Alexander C Ford: none declared. Paul Moayyedi: chair at McMaster University
37
38 partly funded by an unrestricted donation by AstraZeneca, and has received
39
40 consultant's and speaker's bureau fees from AstraZeneca, AxCan Pharma, Nycomed,
41
42 and Johnson and Johnson.
43
44
45
46
47
48
49
50

51 **Declaration of Funding Interests:**

52
53
54 We are grateful to the American College of Gastroenterology for funding a series of
55
56
57
58
59
60 systematic reviews on the management of irritable bowel syndrome.

REFERENCES

1. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. *Gastroenterology* 2006;130:1480-1491.
2. Agreus L, Svardsudd K, Talley NJ, Jones MP, Tibblin G. Natural history of gastroesophageal reflux disease and functional abdominal disorders. *Am J Gastroenterol* 2001;96:2905-2914.
3. Ford AC, Forman D, Bailey AG, Axon ATR, Moayyedi P. Irritable bowel syndrome: A 10-year natural history of symptoms, and factors that influence consultation behavior. *Am J Gastroenterol* 2008;103:1229-1239.
4. Harvey RF, Salih SY, Read AE. Organic and functional disorders in 2000 gastroenterology outpatients. *Lancet* 1983;321:632-634.
5. Koloski NA, Talley NJ, Boyce PM. Epidemiology and health care seeking in the functional GI disorders: A population-based study. *Am J Gastroenterol* 2002;97:2290-2299.
6. Koloski NA, Talley NJ, Huskic SS, Boyce PM. Predictors of conventional and alternative health care seeking for irritable bowel syndrome and functional dyspepsia. *Aliment Pharmacol Ther* 2003;17:841-851.

- 1
2
3 7. May C, Allison G, Chapple A, Chew-Graham C, Dixon C, Gask L, et al.
4
5 Framing the doctor-patient relationship in chronic illness: A comparative study
6
7 of general practitioners' accounts. *Sociol Health Illn* 2004;26:135-158.
8
9
- 10
11
12 8. Sandler RS, Everhart JE, Donowitz M, Adams E, Cronin K, Goodman C, et al.
13
14 The burden of selected digestive diseases in the United States.
15
16 *Gastroenterology* 2002;122:1500-1511.
17
18
- 19
20
21 9. Longstreth GF, Yao JF. Irritable bowel syndrome and surgery: A multivariate
22
23 analysis. *Gastroenterology* 2004;126:1665-1673.
24
25
26
27
- 28 10. Ford AC, Talley NJ, Spiegel BMR, Foxx-Orenstein AE, Schiller L, Quigley
29
30 EMM, et al. Effect of fibre, antispasmodics, and peppermint oil in irritable
31
32 bowel syndrome: Systematic review and meta-analysis. *Br Med J*
33
34 2008;337:1388-1392.
35
36
37
38
39
- 40 11. Ford AC, Talley NJ, Schoenfeld PS, Quigley EMM, Moayyedi P. Efficacy of
41
42 antidepressants and psychological therapies in irritable bowel syndrome:
43
44 Systematic review and meta-analysis. *Gut* 2009;58:367-378.
45
46
47
48
- 49 12. Ford AC, Brandt LJ, Young C, Chey WD, Foxx-Orenstein AE, Moayyedi P.
50
51 Efficacy of 5-HT₃ antagonists and 5-HT₄ agonists in irritable bowel syndrome:
52
53 Systematic review and meta-analysis. *Am J Gastroenterol* 2009;104:1831-
54
55 1843.
56
57
58
59
60

Ford *et al.*

22 of 51

- 1
2
3 13. Design of Treatment Trials Committee, Irvine EJ, Whitehead WE, Chey WD,
4
5 Matsueda K, Shaw M, et al. Design of treatment trials for functional
6
7 gastrointestinal disorders. *Gastroenterology* 2006;130:1538-1551.
8
9
- 10
11
12 14. de Craen AJ, Moerman DE, Heisterkamp SH, Tytgat GN, Tijssen JG, Kleijnen
13
14 J. Placebo effect in the treatment of duodenal ulcer. *Br J Pharmacol*
15
16 1999;48:853-860.
17
18
- 19
20
21 15. Ilnyckyj A, Shanahan F, Anton PA, Cheang M, Bernstein CN. Quantification
22
23 of the placebo response in ulcerative colitis. *Gastroenterology* 1997;112:1854-
24
25 1858.
26
27
- 28
29
30 16. Brandt LJ, Chey WD, Foxx-Orenstein AE, Quigley EMM, Schiller LR,
31
32 Schoenfeld PS, et al. An evidence-based systematic review on the
33
34 management of irritable bowel syndrome. *Am J Gastroenterol* 2009;104 (suppl
35
36 D):S8-S35.
37
38
- 39
40
41 17. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et
42
43 al. Assessing the quality of reports of randomized clinical trials: Is blinding
44
45 necessary? *Control Clin Trials* 1996;17:1-12.
46
47
48
49
- 50
51 18. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials*
52
53 1986;7:177-188.
54
55
56
- 57
58 19. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency
59
60 in meta-analyses. *Br Med J* 2003;327:557-560.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
20. Lau J, Ioannidis JPA, Schmidt CA. Summing up evidence: One answer is not always enough. *Lancet* 1998;351:123-127.
21. Ritchie JA, Truelove SC. Treatment of irritable bowel syndrome with lorazepam, hyoscine butylbromide, and ispaghula husk. *Br Med J* 1979;278:376-378.
22. Kruis W, Weinzierl M, Schussler P, Holl J. Comparison of the therapeutic effects of wheat bran and placebo in patients with the irritable bowel syndrome. *Digestion* 1986;34:196-201.
23. Nigam P, Kapoor KK, Rastog CK, Kumar A, Gupta AK. Different therapeutic regimens in irritable bowel syndrome. *J Assoc Physicians India* 1984;32:1041-1044.
24. Lech Y, Olesen KM, Hey H, Rask-Pedersen E, Vilien M, Ostergaard O. Treatment of irritable bowel syndrome with peppermint oil. A double-blind investigation with a placebo. *Ugeskr Laeger* 1988;150:2388-2389.
25. Liu J-H, Chen G-H, Yeh H-Z, Huang C-K, Poon S-K. Enteric-coated peppermint-oil capsules in the treatment of irritable bowel syndrome: A prospective, randomized trial. *J Gastroenterol* 1997;32:765-768.
26. Cappello G, Spezzaferro M, Grossi L, Manzoli L, Marzio L. Peppermint oil (Mintoil) in the treatment of irritable bowel syndrome: A prospective double blind placebo-controlled randomized trial. *Dig Liver Dis* 2007;39:530-536.

Ford *et al.*

24 of 51

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
27. Schafer VE, Ewe K. The treatment of irritable colon. Efficacy and tolerance of buscopan plus, buscopan, paracetamol and placebo in ambulatory patients with irritable colon. *Fortschr Med* 1990;108:488-492.
28. Centonze V, Imbibo BP, Campanozzi F, Attolini E, Daniotti S, Albano O. Oral cimetropium bromide, a new antimuscarinic drug, for long-term treatment of irritable bowel syndrome. *Am J Gastroenterol* 1988;83:1262-1266.
29. Dobrilla G, Imbibo BP, Piazzzi L, Bensi G. Long term treatment of irritable bowel syndrome with cimetropium bromide: a double blind placebo controlled clinical trial. *Gut* 1990;31:355-358.
30. Passaretti S, Guslandi M, Imbibo BP, Daniotti S, Tittobello A. Effects of cimetropium bromide on gastrointestinal transit time in patients with irritable bowel syndrome. *Aliment Pharmacol Ther* 1989;3:276.
31. Ghidini O, Saponati G, Intrieri L. Single drug treatment for irritable colon: Rociverine versus trimebutine maleate. *Curr Ther Res Clin Exp* 1986;39:541-548.
32. Moshal MG, Herron M. A clinical trial of trimebutine (Mebutin) in spastic colon. *J Int Med Res* 1979;7:231-234.
33. Glende M, Morselli-Labate AM, Battaglia G, Evangelista S. Extended analysis of a double blind, placebo-controlled, 15-week study with otilinium bromide in irritable bowel syndrome. *Eur J Gastroenterol Hepatol* 2002;14:1331-1338.

- 1
2
3 34. Gilvarry J, Kenny A, Fielding JF. The non-effect of pirenzepine in dietary
4
5 resistant irritable bowel syndrome. *Ir J Med Sci* 1989;158:262.
6
7
8
9
- 10 35. Mitchell SA, Mee AS, Smith GD, Palmer KR, Chapman RW. Alverine citrate
11
12 fails to relieve the symptoms of irritable bowel syndrome: Results of a double-
13
14 blind, randomized, placebo-controlled trial. *Aliment Pharmacol Ther*
15
16 2002;16:1187-1195.
17
18
19
- 20 36. Piai G, Mazzacca G. Prifinium bromide in the treatment of the irritable colon
21
22 syndrome. *Gastroenterology* 1979;77:500-502.
23
24
25
26
27
- 28 37. Fielding JF. Double blind trial of trimebutine in the irritable bowel syndrome.
29
30 *Ir Med J* 1980;73:377-379.
31
32
33
- 34 38. Page JG, Dirnberger GM. Treatment of the irritable bowel syndrome with
35
36 Bentyl (dicyclomine hydrochloride). *J Clin Gastroenterol* 1981;3:153-156.
37
38
39
- 40 39. Levy C, Charbonnier A, Cachin M. Pinaverium bromide and functional
41
42 colonic disease (double-blind study). *Sem Hop Ther* 1977;53:372-374.
43
44
45
46
47
- 48 40. D'Arienzo A, D'Agostino L. L'ottilonio bromuro nel trattamento della
49
50 s ndrome del colon irritabile. *Rass Int Clin Ter* 1980;60:649-656.
51
52
53
54
- 55 41. Virat J, Hueber D. Colopathy pain and dicetel. *Prat Med* 1987;43:32-34.
56
57
58
59
60

Ford *et al.*

26 of 51

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
42. Drossman DA, Toner BB, Whitehead WE, Diamant NE, Dalton CB, Duncan S, et al. Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders. *Gastroenterology* 2003;125:19-31.
43. Talley NJ, Kellow JE, Boyce P, Tennant C, Huskic S, Jones M. Antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: A double-blind, randomized, placebo-controlled trial. *Dig Dis Sci* 2008;53:108-115.
44. Vahedi H, Merat S, Rashidioon A, Ghoddoosi A, Malekzadeh R. The effect of fluoxetine in patients with pain and constipation-predominant irritable bowel syndrome: A double-blind randomized-controlled study. *Aliment Pharmacol Ther* 2005;22:381-385.
45. Heefner JD, Wilder RM, Wilson ID. Irritable colon and depression. *Psychosomatics* 1978;19:540-547.
46. Kuiken SD, Tytgat GNJ, Boeckxstaens GEE. The selective serotonin reuptake inhibitor fluoxetine does not change rectal sensitivity and symptoms in patients with irritable bowel syndrome: A double-blind, randomized, placebo-controlled study. *Clin Gastroenterol Hepatol* 2003;1:219-228.
47. Tabas G, Beaves M, Wang J, Friday P, Mardini H, Arnold G. Paroxetine to treat irritable bowel syndrome not responding to high fiber diet: A double-blind placebo-controlled trial. *Am J Gastroenterol* 2004;99:914-920.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
48. Boerner D, Eberhardt R, Metz K, Schick E. Wirksamkeit und verträglichkeit eines antidepressivums beim colon irritabile. *Therapiewoche* 1988;38:201-208.
 49. Tack J, Broekaert D, Fischler B, van Oudenhove L, Gevers AM, Janssens J. A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome. *Gut* 2006;55:1095-1103.
 50. Vij JC, Jiloha RC, Kumar N, Madhu SV, Malika V, Anand BS. Effect of antidepressant drug (doxepin) on irritable bowel syndrome patients. *Indian J Psychiatry* 1991;33:243-246.
 51. Myren J, Groth H, Larssen SE, Larsen S. The effect of trimipramine in patients with the irritable bowel syndrome: A double-blind study. *Scand J Gastroenterol* 1982;17:871-875.
 52. Vahedi H, Merat S, Momtahan S, Kazzazi AS, Ghaffari N, Olfati G, et al. Clinical trial: The effect of amitriptyline in patients with diarrhea-predominant irritable bowel syndrome. *Aliment Pharmacol Ther* 2008;27:678-684.
 53. Bergmann M, Heddergott A, Schlosser T. Die therapie des colon irritabile mit trimipramin (Herphonal) - Eine kontrollierte studie. *Z Klin Med* 1991;46:1621-1628.
 54. Baldi F, Corinaldesi R, Ferrarini F, Balestra R, Brunetti G, Cassan M, et al. Clinical and functional evaluation of octilonium bromide in the treatment of

- 1
2
3 irritable bowel syndrome: A double-blind controlled trial. *Clin Trials J*
4
5 1983;20:77-88.
6
7
8
9
- 10 55. Castiglione F, Daniele B, Mazzacca G. Therapeutic strategy for the irritable
11
12 bowel syndrome. *Ital J Gastroenterol* 1991;23 (suppl 1):53-55.
13
14
15
16
- 17 56. Delmont J. Interet de l'adjonction d'un antispasmodique musculotrope au
18
19 traitement des constipations douloureuses des colopathies fonctionnelles par le
20
21 son. *Med Chir Dig* 1981;10:365-370.
22
23
24
25
- 26 57. Pulpeiro A, Marti ML, De Los Santos AR, Di Girolamo G. Propinox en
27
28 syndrome de intestino irritable. *Prensa Med Argent* 2000;87:299-307.
29
30
31
32
- 33 58. Capanni M, Surrenti E, Biagini M, Milani S, Surrenti C, Galli A. Efficacy of
34
35 peppermint oil in the treatment of irritable bowel syndrome: A randomized,
36
37 controlled trial. *Gazz Med Ital* 2005;164:119-126.
38
39
40
41
- 42 59. Camilleri M, Mayer EA, Drossman DA, Heath A, Dukes GE, McSorley D, et
43
44 al. Improvement in pain and bowel function in female irritable bowel patients
45
46 with alosetron, a 5-HT₃ receptor antagonist. *Aliment Pharmacol Ther*
47
48 1999;13:1149-1159.
49
50
51
52
- 53 60. Lembo T, Wright RA, Lotronex Investigator Team, Bagby B, Decker C,
54
55 Gordon S, et al. Alosetron controls bowel urgency and provides global
56
57 symptom improvement in women with diarrhea-predominant irritable bowel
58
59 syndrome. *Am J Gastroenterol* 2001;96:2662-2670.
60

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61. Bardhan KD, Bodemar G, Geldof H, Schutz E, Heath A, Mills JG, et al. A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome. *Aliment Pharmacol Ther* 2000;14:23-34.
 62. Camilleri M, Northcutt AR, Kong S, Dukes GE, McSorley D, Mangel AW. Efficacy and safety of alosetron in women with irritable bowel syndrome: A randomised, placebo-controlled trial. *Lancet* 2000;355:1035-1040.
 63. Camilleri M, Chey WY, Mayer EA, Northcutt AR, Heath A, Dukes GE, et al. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. *Arch Intern Med* 2001;161:1733-1740.
 64. Krause R, Ameen V, Gordon SH, West M, Heath AT, Perschy T, et al. A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS. *Am J Gastroenterol* 2007;102:1709-1719.
 65. Masand PS, Pae C-U, Krulewicz S, Peindl K, Mannelli P, Varia IM, et al. A double-blind, randomized, placebo-controlled trial of paroxetine controlled-release in irritable bowel syndrome. *Psychosomatics* 2009;50:78-86.
 66. Abdul-Baki H, El Hajj II, ElZahabi L, Azar C, Aoun E, Skoury A, et al. A randomized controlled trial of imipramine in patients with irritable bowel syndrome. *World J Gastroenterol* 2009;15:3636-3642.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
67. Matsueda K, Harasawa S, Hongo M, Hiwatashi N, Sasaki D. A randomized, double-blind, placebo-controlled clinical trial of the effectiveness of the novel serotonin type 3 receptor antagonist ramosetron in both male and female Japanese patients with diarrhea-predominant irritable bowel syndrome. *Scand J Gastroenterol* 2008;43:1202-1211.
68. Ladabaum U, Sharabidze A, Levin TR, Zhao WK, Chung E, Bacchetti P, et al. Citalopram is not effective therapy for nondepressed patients with irritable bowel syndrome. *Clin Gastroenterol Hepatol* 2010;8:42-48.
69. Merat S, Khalili S, Mostajabi P, Ghorbani A, Ansari R, Malekzadeh R. The effect of enteric-coated, delayed-release peppermint oil on irritable bowel syndrome. *Dig Dis Sci* 2010;(in press).
70. Matsueda K, Harasawa S, Hongo M, Hiwatashi N, Sasaki D. A phase II trial of the novel serotonin type 3 receptor antagonist ramosetron in Japanese male and female patients with diarrhea-predominant irritable bowel syndrome. *Digestion* 2008;77:225-235.
71. Chang L, Ameen VZ, Dukes GE, McSorley D, Carter EG, Mayer EA. A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS. *Am J Gastroenterol* 2005;100:115-123.
72. Chey WD, Chey WY, Heath AT, Dukes GE, Carter EG, Northcutt AR, et al. Long-term safety and efficacy of alosetron in women with severe diarrhea-

1
2
3 predominant irritable bowel syndrome. *Am J Gastroenterol* 2004;99:2195-
4
5 2203.
6
7
8
9

10 73. Bradette M, Moennikes H, Carter F, Krause G, Caras S, Steinborn C.
11
12 Cilansetron in irritable bowel syndrome with diarrhea predominance (IBS-D):
13
14 Efficacy and safety in a 6 month global study. *Gastroenterology* 2004;126
15
16 (suppl 2):A42.
17
18

19
20
21 74. Francisconi CF, Drossman DA, Mayer EA, Caras S. Interruption of daily
22
23 activities in cilansetron-treated patients with irritable bowel syndrome with
24
25 diarrhea-predominance (IBS-D): Results from a 16-week, placebo-controlled,
26
27 rerandomization trial. *Gastroenterology* 2006;130 (suppl 2):A600.
28
29
30

31
32
33 75. Miner P, Stanton D, Carter F, Caras S, Krause G, Steinborn C. Cilansetron in
34
35 irritable bowel syndrome with diarrhea predominance (IBS-D): Efficacy and
36
37 safety in a 3 month US study. *Am J Gastroenterol* 2004;99 (suppl):S277.
38
39
40

41
42 76. Muller-Lissner SA, Fumagalli I, Bardhan KD, Pace F, Pecher E, Nault B, et al.
43
44 Tegaserod, a 5-HT₄ receptor partial agonist, relieves symptoms in irritable
45
46 bowel syndrome patients with abdominal pain, bloating and constipation.
47
48
49 *Aliment Pharmacol Ther* 2001;15:1655-1666.
50
51

52
53
54 77. Tack J, Muller-Lissner S, Bytzer P, Corinaldesi R, Chang L, Viegas A, et al. A
55
56 randomised controlled trial assessing the efficacy and safety of repeated
57
58 tegaserod therapy in women with irritable bowel syndrome with constipation.
59
60
61 *Gut* 2005;54:1707-1713.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
78. Novick J, Miner P, Krause R, Glebass K, Bliesath H, Ligozio G, et al. A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. *Aliment Pharmacol Ther* 2002;16:1877-1888.
79. Kellow J, Lee OY, Chang FY, Thongsawat S, Mazlam MZ, Yuen H, et al. An Asia-Pacific, double-blind, placebo-controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome. *Gut* 2003;52:671-676.
80. Harish K, Hazeena K, Varghese T, Kumar S, Jose T, Narayanan P. Effect of tegaserod on colonic transit time in male patients with constipation-predominant irritable bowel syndrome. *J Gastroenterol Hepatol* 2007;22:1183-1189.
81. Nyhlin H, Bang C, Elsborg L, Silvennoinen J, Holme I, Ruegg P, et al. A double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome. *Scand J Gastroenterol* 2004;39:119-126.
82. Hamling J, Bang CJ, Tarpila S, Stewart W, Ruegg P. Titration regimen indicates partial 5-HT₄ agonist HTF 919 improves symptoms of constipation predominant irritable bowel syndrome (C-IBS). *Digestion* 1998;59 (suppl 3):735.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
83. Langaker KJ, Morris D, Pruitt R, Otten M, Stewart W, Ruegg P. The partial 5-HT₄ agonist (HTF 919) improves symptoms in constipation-predominant irritable bowel syndrome (C-IBS). *Digestion* 1998;59 (suppl 3):20.
84. Novartis Pharmaceuticals Corporation. ZelmacTM (tegaserod) advisory committee briefing document.
www.fda.gov/ohrms/dockets/ac/00/backgrd/3627b1a.pdf Accessed 20th July 2008.
85. Spiller RC, Meyers NL, Hickling RI. Identification of patients with non-D, non-C irritable bowel syndrome and treatment with renzapride: An exploratory, multicenter, randomized, double-blind, placebo-controlled clinical trial. *Dig Dis Sci* 2008;53:3191-3200.
86. Camilleri M, McKinzie S, Fox J, Foxx-Orenstein A, Burton D, Thomforde G, et al. Effect of renzapride on transit in constipation-predominant irritable bowel syndrome. *Clin Gastroenterol Hepatol* 2004;2:895-904.
87. George AM, Meyers NL, Hickling RI. Clinical trial: Renzapride therapy for constipation-predominant irritable bowel syndrome - multicentre, randomized, placebo-controlled, double-blind study in primary healthcare setting. *Aliment Pharmacol Ther* 2008;27:830-837.
88. Schutze K, Brandstatter G, Dragosics B, Judmaier G, Hentschel E. Double-blind study of the effect of cisapride on constipation and abdominal discomfort

- 1
2
3 as components of the irritable bowel syndrome. *Aliment Pharmacol Ther*
4
5 1997;11:387-394.
6
7
8
9
- 10 89. Van Outryve M, Milo R, Toussaint J, Van Eeghem P. "Prokinetic" treatment
11 of constipation-predominant irritable bowel syndrome: A placebo-controlled
12 study of cisapride. *J Clin Gastroenterol* 1991;13:49-57.
13
14
15
16
17
18
- 19 90. Ziegenhagen DJ, Kruis W. Cisapride treatment of constipation-predominant
20 irritable bowel syndrome is not superior to placebo. *J Gastroenterol Hepatol*
21 2004;19:744-749.
22
23
24
25
26
27
- 28 91. Farup PG, Hovdenak N, Wetterhus S, Lange OJ, Hovde O, Trondstad R. The
29 symptomatic effect of cisapride in patients with irritable bowel syndrome and
30 constipation. *Scand J Gastroenterol* 1998;33:128-131.
31
32
33
34
35
36
- 37 92. Chey WD, Pare P, Viegas A, Ligozio G, Shetzline M. Tegaserod for female
38 patients suffering from IBS with mixed bowel habits or constipation: A
39 randomized controlled trial. *Am J Gastroenterol* 2008;103:1217-1225.
40
41
42
43
44
45
- 46 93. Patel SM, Stason WB, Legedza A, Ock SM, Kaptchuk TJ, Conboy L, et al.
47 The placebo effect in irritable bowel syndrome trials: a meta-analysis.
48 *Neurogastroenterol Motil* 2005;17:332-340.
49
50
51
52
53
54
- 55 94. Juni P, Altman DG, Egger M. Assessing the quality of controlled clinical trials.
56 *Br Med J* 2001;323:42-46.
57
58
59
60

Ford *et al.*

35 of 51

- 1
2
3 95. Investigation of the safety and efficacy of renzapride in constipation
4 predominant irritable bowel syndrome.
5
6

7
8 <http://www.clinicaltrial.gov/ct2/show/NCT00268879> Accessed 29th January
9
10 2010.
11

- 12
13
14 96. Renzapride. <http://www.alizyme.com/alizyme/products/renzapride/> Accessed
15
16 29th January 2010.
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review

Ford *et al.*

36 of 51

Box 1. Eligibility criteria.

Randomised controlled trials

Adults (participants aged > 16 years)

Diagnosis of irritable bowel syndrome based on either a clinician's opinion, or meeting specific diagnostic criteria*, supplemented by negative investigations where trials deemed this necessary.

Compared pharmacological therapies† with placebo.

Minimum duration of therapy 7 days.

Global assessment of irritable bowel syndrome symptoms or abdominal pain following therapy.‡

*Manning, Kruis score, Rome I, II, or III.

†Antispasmodics, peppermint oil, antidepressants, 5-HT₃ antagonists, 5-HT₄ agonists, and mixed 5-HT₃ antagonists / 5-HT₄ agonists.

‡Preferably patient-reported, but if this was not available then as assessed by a physician or questionnaire data.

Ford *et al.*

37 of 51

Box 2. Data extraction methodology.

Outcome of interest: improvement in or absence of global irritable bowel syndrome symptoms preferable, if not reported then improvement in or absence of abdominal pain.

Reporting of outcomes: patient-reported preferable, if not available then investigator-reported.

Time of assessment: upon completion of therapy.

Denominator used: true intention-to-treat analysis, if not available then all evaluable patients.

For Peer Review

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Ford *et al.*

38 of 51

Box 3. Jadad score calculation


Item	Score
Was the study described as randomised?	1
Was the method used to generate the sequence of randomisation described and appropriate (random numbers, computer-generated, etc)?	1
Was the study described as double-blind?	1
Was the method of double-blinding described and appropriate (identical placebo, active placebo, dummy, etc)?	1
Was there a description of withdrawals and drop-outs?	1
Deduct one point if method used to generate sequence of randomisation described, but inappropriate (allocated alternately, or according to date of birth, or hospital number).	-1
Deduct one point if study described as double-blind, but method of blinding inappropriate.	-1

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Pre-Review

FIGURES


Figure 1. Flow Diagram of Assessment of Trials Identified in the Systematic Review.



Ford *et al.*

40 of 51

Figure 2. L'Abbe Plot of Placebo Response Rates (The Solid Line Represents Equality Between Experimental Treatment and Control, with Circles Above this Line Representing Trials Where Experimental Treatment was Superior to Control).



Ford *et al.*

41 of 51

TABLES

Table 1. Characteristics of Included Trials.

Trial	Geographical location	Number of centres	Criteria used to define IBS*	Active treatment	Duration of therapy	Dosing schedule†	Sample size	Placebo response rate (%)	Jadad score
Heefner 1978 ⁴⁵	North America	Multiple	Clinical	Desimipramine	8 weeks	o.d.	44	10/22 (45.5)	4
Myren 1982 ⁵¹	Europe	Multiple	Clinical	Trimipramine	4 weeks	o.d.	61	21/31 (67.7)	2
Nigam 1984 ²³	Asia	Single	Clinical	Amitriptyline	12 weeks	o.d.	42	0/21 (0)	3
Boerner 1988 ⁴⁸	Europe	Single	Clinical	Doxepin	8 weeks	o.d.	83	22/41 (53.7)	4
Bergmann 1991 ⁵³	Europe	Single	Clinical	Trimipramine	12 weeks	o.d.	35	2/16 (12.5)	2
Vij 1991 ⁵⁰	Asia	Single	Clinical	Doxepin	6 weeks	o.d.	50	5/25 (20.0)	5
Drossman 2003 ⁴²	North America	Multiple	Rome I	Desipramine	12 weeks	o.d.	172	21/57 (36.8)	5
Kuiken 2003 ⁴⁶	Europe	Single	Rome I	Fluoxetine	6 weeks	o.d.	40	9/21 (42.9)	5
Tabas 2004 ⁴⁷	North America	Single	Rome I	Paroxetine	12 weeks	o.d.	90	10/46 (21.7)	5
Vahedi 2005 ⁴⁴	Middle East	Single	Rome II	Fluoxetine	12 weeks	o.d.	44	3/22 (13.6)	5
Tack 2006 ⁴⁹	Europe	Single	Rome II	Citalopram	6 weeks	o.d.	23	1/12 (8.3)	4

Ford *et al.*

42 of 51

Talley 2008 ⁴³	Australasia	Multiple	Rome II	Citalopram and imipramine	12 weeks	o.d.	33	11/16 (68.8)	5
Vahedi 2008 ⁵²	Middle East	Single	Rome II	Amitriptyline	8 weeks	o.d.	54	11/27 (40.7)	5
Abdul-Baki 2009 ⁶⁶	Middle East	Single	Rome II	Imipramine	12 weeks	Titrated	107	12/48 (25.0)	5
Masand 2009 ⁶⁵	North America	Multiple	Rome II	Paroxetine	12 weeks	o.d.	72	6/36 (16.7)	4
Ladabaum 2010 ⁶⁸	North America	Multiple	Rome II	Citalopram	8 weeks	o.d.	54	15/27 (55.6)	5
Levy 1977 ³⁹	Europe	Single	Clinical	Pinaverium	2 weeks	t.i.d.	50	7/25 (28.0)	3
Moshal 1979 ³²	Africa	Single	Clinical	Trimebutine	4 weeks	t.i.d.	20	6/10 (60.0)	4
Piai 1979 ³⁶	Europe	Single	Clinical	Prifinium	3 weeks	t.i.d.	18	3/9 (33.3)	4
Ritchie 1979 ²¹	Europe	Single	Clinical	Hyoscine	12 weeks	q.i.d.	24	0/12 (0)	4
D'Arienzo 1980 ⁴⁰	Europe	Single	Clinical	Octilonium	4 weeks	t.i.d.	28	10/14 (71.4)	3
Fielding 1980 ³⁷	Europe	Single	Clinical	Trimebutine	24 weeks	t.i.d.	60	17/30 (56.7)	3
Delmont 1981 ⁵⁶	Europe	Single	Clinical	Pinaverium	4 weeks	t.i.d.	60	17/30 (56.7)	4
Page 1981 ³⁸	North America	Multiple	Clinical	Dicycloverine	2 weeks	q.i.d.	97	16/49 (32.7)	4
Baldi 1983 ⁵⁴	Europe	Single	Clinical	Otilonium	4 weeks	t.i.d.	30	8/15 (53.3)	4
Ghidini 1986 ³¹	Europe	Single	Clinical	Rociverine and trimebutine	8 weeks	t.i.d.	60	20/30 (66.7)	3

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Ford *et al.*

43 of 51

Kruis 1986 ²²	Europe	Single	Clinical	Mebeverine	16 weeks	q.i.d.	80	12/40 (30.0)	4
Virat 1987 ⁴¹	Europe	Single	Clinical	Pinaverium	1 week	t.i.d.	78	13/39 (33.3)	2
Centonze 1988 ²⁸	Europe	Single	Clinical	Cimetropium	24 weeks	t.i.d.	48	5/24 (20.8)	4
Gilvarry 1989 ³⁴	Europe	Single	Clinical	Pirenzipine	4 weeks	b.i.d.	24	6/12 (50.0)	4
Passaretti 1989 ³⁰	Europe	Single	Clinical	Cimetropium	4 weeks	t.i.d.	40	8/20 (40.0)	4
Dobrilla 1990 ²⁹	Europe	Single	Clinical	Cimetropium	12 weeks	t.i.d.	70	24/35 (68.6)	4
Schafer 1990 ²⁷	Europe	Single	Clinical	Hyoscine	4 weeks	t.i.d.	360	114/178 (64.0)	3
Castiglione 1991 ⁵⁵	Europe	Single	Clinical	Otilonium	4 weeks	Not stated	60	10/30 (33.3)	2
Pulpeiro 2000 ⁵⁷	South America	Single	Clinical	Propinox	4 weeks	Not stated	75	33/36 (91.7)	3
Glende 2002 ³³	Multiple	Multiple	Rome I	Otilonium	15 weeks	t.i.d.	317	36/160 (22.5)	3
Mitchell 2002 ³⁵	Europe	Multiple	Rome II	Alverine	12 weeks	t.i.d.	107	23/54 (42.6)	5
Lech 1988 ²⁴	Europe	Single	Clinical	Peppermint oil	4 weeks	t.i.d.	47	6/24 (25.0)	3
Liu 1997 ²⁵	Asia	Single	Clinical	Peppermint oil	4 weeks	q.i.d.	110	21/55 (38.2)	4
Capanni 2005 ⁵⁸	Europe	Single	Rome II	Peppermint oil	12 weeks	t.i.d.	178	31/87 (35.6)	5
Cappello 2007 ²⁶	Europe	Single	Rome II	Peppermint oil	8 weeks	b.i.d.	57	10/29 (34.5)	5
Merat 2010 ⁶⁹	Middle East	Single	Rome II	Peppermint oil	8 weeks	t.i.d.	90	6/45 (13.3)	5
Camilleri 1999 ⁵⁹	North America	Multiple	Rome I	Alosetron	12 weeks	b.i.d.	370	26/80 (32.5)	4

Ford *et al.*

44 of 51

Bardhan 2000 ⁶¹	Europe	Multiple	Rome I	Alosetron	12 weeks	b.i.d.	462	60/117 (51.3)	4
Camilleri 2000 ⁶²	North America	Multiple	Rome I	Alosetron	12 weeks	b.i.d.	647	94/323 (29.1)	5
Camilleri 2001 ⁶³	North America	Multiple	Rome I	Alosetron	12 weeks	b.i.d.	626	82/317 (25.9)	5
Lembo 2001 ⁶⁰	North America	Multiple	Rome II	Alosetron	12 weeks	b.i.d.	801	113/269 (42.0)	4
Chey 2004 ⁷²	Multiple	Multiple	Rome I	Alosetron	48 weeks	b.i.d.	714	166/363 (45.7)	4
Chang 2005 ⁷¹	North America	Single	Rome I	Alosetron	12 weeks	b.i.d.	662	51/128 (39.8)	4
Krause 2007 ⁶⁴	North America	Multiple	Rome II	Alosetron	12 weeks	b.i.d.	705	54/176 (30.7)	5
Bradette 2004 ⁷³	Not stated	Not stated	Rome ‡	Cilansetron	24 weeks	t.i.d.	792	179/397 (45.1)	3
Miner 2004 ⁷⁵	North America	Not stated	Rome ‡	Cilansetron	12 weeks	t.i.d.	692	97/348 (27.9)	3
Francisconi 2006 ⁷⁴	Not stated	Not stated	Rome ‡	Cilansetron	12 weeks	t.i.d.	745	116/368 (31.5)	3
Matsueda 2008 ⁶⁷	Asia	Multiple	Rome II	Ramosetron	12 weeks	o.d.	539	71/269 (26.4)	4
Matsueda 2008 ⁷⁰	Asia	Multiple	Rome II	Ramosetron	12 weeks	o.d.	418	28/109 (25.7)	4
Hamling 1998 ⁸²	Not stated	Multiple	Rome I	Tegaserod	20 weeks	b.i.d.	123	9/38 (23.7)	3
Langaker 1998 ⁸³	Not stated	Multiple	Rome I	Tegaserod	12 weeks	b.i.d.	547	28/113 (24.8)	3
Muller-Lissner 2001 ⁷⁶	Multiple	Multiple	Rome I	Tegaserod	12 weeks	b.i.d.	881	99/288 (34.4)	4
Novick 2002 ⁷⁸	North America	Multiple	Rome I	Tegaserod	12 weeks	b.i.d.	1519	292/752 (38.8)	5
Kellow 2003 ⁷⁹	Multiple	Multiple	Rome II	Tegaserod	12 weeks	b.i.d.	520	140/261 (53.6)	5

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Ford *et al.*

45 of 51

Nyhlin 2004 ⁸¹	Europe	Multiple	Rome II	Tegaserod	12 weeks	b.i.d.	647	90/320 (28.1)	5
Tack 2005 ⁷⁷	Multiple	Multiple	Rome II	Tegaserod	4 weeks	b.i.d.	2660	209/525 (39.8)	5
Harish 2007 ⁸⁰	Asia	Single	Rome II	Tegaserod	12 weeks	b.i.d.	40	10/20 (50.0)	5
Chey 2008 ⁹²	North America	Multiple	Rome II	Tegaserod	4 weeks	b.i.d.	661	128/332 (38.6)	5
B307 ⁸⁴	Multiple	Multiple	Rome I	Tegaserod	12 weeks	b.i.d.	845	105/285 (36.8)	4
B351 ⁸⁴	Multiple	Multiple	Rome I	Tegaserod	12 weeks	b.i.d.	799	59/267 (22.1)	4
Camilleri 2004 ⁸⁶	North America	Single	Rome II	Renzapride	2 weeks	o.d.	48	2/12 (16.7)	4
George 2008 ⁸⁷	Europe	Multiple	Rome II	Renzapride	12 weeks	o.d.	510	36/125 (28.8)	4
Spiller 2008 ⁸⁵	Europe	Multiple	Rome II	Renzapride	8 weeks	o.d.	168	23/42 (54.8)	5
Van Outryve 1991 ⁸⁹	Europe	Single	Clinical	Cisapride	12 weeks	t.i.d.	69	11/33 (33.3)	4
Schutze 1997 ⁸⁸	Europe	Multiple	Rome I	Cisapride	12 weeks	t.i.d.	96	34/48 (70.8)	4
Farup 1998 ⁹¹	Europe	Multiple	Rome I	Cisapride	12 weeks	t.i.d.	70	20/37 (54.1)	4
Ziegenhagen 2004 ⁹⁰	Europe	Multiple	Rome I	Cisapride	12 weeks	t.i.d.	82	20/42 (47.6)	4

*Irritable bowel syndrome

†o.d. once daily, b.i.d. twice daily, t.i.d. three times daily, q.i.d. four times daily

‡Iteration of Rome criteria not specified

Ford *et al.*

46 of 51

Table 2. Effect of Trial Characteristics on Magnitude of the Placebo Response.

	Number of trials	Number of patients receiving placebo	Pooled placebo response rate (%)	95% confidence interval	I ² (%)	P value for <u>I²</u>
All trials	73	8364	37.5	34.4 – 40.6	86.2	< 0.001
<u>Year of publication</u>						
<u>Before 1999</u>	<u>33</u>	<u>1700</u>	<u>39.0</u>	<u>33.0 – 46.0</u>	<u>86.5</u>	<u>< 0.001</u>
<u>1999 or later</u>	<u>40</u>	<u>6706</u>	<u>36.1</u>	<u>32.7 – 39.5</u>	<u>86.2</u>	<u>< 0.001</u>
<u>Trial location</u>						
Asia	6	499	25.0	16.0 – 36.0	80.5	< 0.001
Europe	33	1622	42.7	36.6 – 48.8	82.7	< 0.001
Middle-East	4	142	23.0	13.0 – 35.0	61.5	0.05
North America	16	2974	33.0	30.0 – 37.0	73.8	< 0.001

Ford *et al.*

47 of 51

Trial setting						
Secondary care	21	663	39.0	31.0 – 48.0	79.2	< 0.001
Tertiary care	20	673	37.0	26.2 – 48.4	88.6	< 0.001
Number of centres						
Single	37	1301	36.9	30.1 – 44.0	85.2	< 0.001
Multi	33	5950	38.0	34.0 – 41.0	86.8	< 0.001
Criteria used to define IBS*						
Clinical	28	906	42.0	33.0 – 51.0	85.9	< 0.001
Rome I	19	3482	36.0	31.0 – 41.0	86.6	< 0.001
Rome II	23	2863	34.4	29.8 – 39.2	82.6	< 0.001
Predominant stool pattern						
Constipation	16	2617	36.0	31.0 – 42.0	82.7	< 0.001
Diarrhoea	8	1822	33.0	28.0 – 39.0	83.0	< 0.001

For Peer Review

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Ford *et al.*

48 of 51

Criteria used to define response						
Patient-reported	66	8122	37.4	34.2 – 40.6	87.0	< 0.001
Physician-reported	4	81	53.0	42.0 – 63.0	0	0.64
Symptom data used to define response						
Abdominal pain	13	1622	35.0	29.0 – 42.0	83.8	< 0.001
Global symptoms	54	6175	38.0	35.0 – 42.0	87.4	< 0.001
Dosing schedule†						
o.d.	20	977	32.2	25.2 – 39.7	81.1	< 0.001
b.i.d.	21	5015	36.0	32.0 – 40.0	85.8	< 0.001
t.i.d.	25	2102	43.0	37.0 – 50.0	87.2	< 0.001

For Peer Review

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Ford *et al.*

49 of 51

Duration of therapy						
1 – 4 weeks	19	1446	46.0	39.0 – 54.0	83.8	< 0.001
5 – 8 weeks	11	321	39.8	28.7 – 51.4	78.3	< 0.001
> 8 weeks	43	6597	34.0	31.0 – 37.0	86.8	< 0.001
Proportion of trial patients assigned to placebo						
Approximately 50%	57	5733	38.7	34.7 – 42.7	87.7	< 0.001
Significantly less than 50%	16	2631	34.0	30.0 – 39.0	79.0	< 0.001

For Peer Review

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Ford *et al.*

50 of 51

Active pharmacological therapy						
Antidepressant	16	468	32.0	22.4 – 42.5	82.4	< 0.001
Antispasmodic	21	852	45.0	35.0 – 55.0	87.9	< 0.001
Peppermint oil	5	240	30.0	21.0 – 40.0	62.1	0.03
5-HT ₃ antagonist	13	3264	35.0	30.0 – 40.0	87.6	< 0.001
5-HT ₄ agonist	11	3201	35.0	30.0 – 40.0	88.3	< 0.001
Mixed 5-HT ₃ antagonists / 5-HT ₄ agonists	7	339	45.0	31.0 – 58.0	83.2	< 0.001
Generation of randomisation schedule						
Stated	27	3811	35.0	31.0 – 40.0	83.0	< 0.001
Not stated or unclear	46	4553	38.8	34.5 – 43.3	87.8	< 0.001

For Peer Review

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Ford *et al.*

51 of 51

Concealment of allocation						
Stated	7	895	37.0	29.0 – 45.0	74.2	< 0.001
Not stated or unclear	66	7469	37.5	34.2 – 40.9	87.0	< 0.001
Score on Jadad scale						
3	14	1782	40.0	30.0 – 50.0	93.9	< 0.001
4	32	2894	37.8	33.3 – 42.5	81.7	< 0.001
5	23	3572	36.0	31.0 – 40.0	81.9	< 0.001

*Irritable bowel syndrome

†o.d. once daily, b.i.d. twice daily, t.i.d. three times daily

Section/topic	#	Checklist item
TITLE		
Title	1	Identify the report as a systematic review, meta-analysis, or both.
ABSTRACT		
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; participants, and interventions; study appraisal and synthesis methods; results; limitations; implications of key findings; systematic review registration number.
INTRODUCTION		
Rationale	3	Describe the rationale for the review in the context of what is already known.
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, outcomes, and study design (PICOS).
METHODS		
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and registration information including registration number.
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., language, publication status) used as criteria for eligibility, giving rationale.
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors for additional studies) in the search and date last searched.
Search	8	Present full electronic search strategy for at least one database, including any limits used, and how they were repeated.
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and included in the meta-analysis).
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and methods for obtaining and confirming data from investigators.
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and describe any simplifications made.
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of where data were obtained on risk of bias, how this information is to be used in any data synthesis, and the measures of risk of bias used in the synthesis), and how this information is to be used in any data synthesis.
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2) for each meta-analysis.

Page 1 of 2

Section/topic	#	Checklist item
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, reporting within studies).
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), including how they were pre-specified.
RESULTS		
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, funding sources) and provide the citations.
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (e.g., RoB 2.0, ROBINS-I).
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary of effects and (b) effect estimates and confidence intervals, ideally with a forest plot.
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency (e.g., I^2).

1	Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).
2	Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression).
3	DISCUSSION		
4	Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; compare key groups (e.g., healthcare providers, users, and policy makers).
5	Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., identified research, reporting bias).
6	Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for practice.
7	FUNDING		
8	Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data for the systematic review).

16 From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097

17 For more information, visit: www.prisma-statement.org.

18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review